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18 The Journal of Thoracic and Cardiobjective: To overcome problems related to the intramyocardial injection of
ells, including cell loss and a limited graft area, we developed a cell delivery
ystem that uses tissue-engineered myoblast grafts grown as sheets. Here, we
ssessed the feasibility and efficacy of our method in a canine dilated cardiomyop-
thy model.
ethods: Skeletal myoblasts were incubated on temperature-responsive culture
ishes, and the sheets of cells were detached by decreasing the temperature.
welve dogs were given continuous ventricular pacing at 230 beats/min for 4
eeks; then the myoblast sheets (n  5) were grafted onto the left ventricular
all or a sham operation was performed (n  7). The number of cells was
djusted to 1.52.5  106 cells per graft, and each dog received approximately 20
rafts.
esults: The cell sheets were easily grafted onto a large area of the left ventricular
urface, and there were no serious sequelae. Four weeks after graft implantation,
chocardiography demonstrated that the left ventricular ejection fraction (graft,
6.0%  5.6%; control, 19.5%  6.8%; P  .05) and fractional shortening (graft,
7.9% 3.6%; control, 7.8% 2.1%; P .05) were significantly ameliorated with
educed left ventricular dilatation (graft, 7.3  1.3 cm2; control, 10.2  0.4 cm2;
 .05) and increased wall thickness (graft, 5.6  0.7 mm; control, 4.4  0.6 mm;
 .05). Histologic evidence indicated the grafted myoblasts had survived, ac-
ompanied by a significant reduction in fibrosis and apoptosis, and a significant
ncrease in proliferation.
onclusions: Grafting of skeletal myoblast sheets attenuated cardiac remodeling and
mproved cardiac performance. This novel method was feasible and effective in a
arge animal model, suggesting an innovative and promising strategy for treating
atients with end-stage dilated cardiomyopathy.
ell transplantation (Tx) into impaired myocardium, also known as cellular
cardiomyoplasty, has been widely investigated,1,2 and various type of cel
including fetal cardiomyocytes,3 embryonic stem cells,4 fibroblasts,5 smooth
uscle cells,6 endothelial cells,7 bone marrow stem cells,8 and skeletal myoblasts,9
ave been used for the therapy. Among them, autologous bone marrow stem cells
nd skeletal myoblasts are considered the most likely to be successful and have been
sed clinically to treat ischemic cardiomyopathy.10-12 In these clinical cases, t
sual method of cell Tx into the myocardium is direct intramyocardial injection with
fine needle. However, this needle injection method has some disadvantages,
ncluding cell loss caused by leakage of injected cells from the myocardium,12 poor
urvival of the grafted cells, myocardial damage after mechanical injury by the
eedle, and subsequent acute inflammation.3,13
vascular Surgery ● October 2006
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PAnother problem accompanying the injection method is
ifficulty in transplanting cells over a large area. Clinical
reatment for diffusely impaired myocardium, such as that
een in dilated cardiomyopathy (DCM), may require a tech-
ique with fewer disadvantages.
To resolve these difficulties, we recently developed a
ovel cell delivery system that uses a tissue-engineered
heet of autologous skeletal myoblasts for grafting; the
heet is fabricated on temperature-responsive culture sur-
aces coated with a temperature-responsive polymer, poly(N-
so-propylacrylamide). Simply by reducing the temperature,
nd without enzymatic digestion, confluent cells on these
urfaces can be harvested as a single, unsupported, contig-
ous sheet. Intercellular junctions form in the sheets, and
xtracellular matrix is retained on the basal surface: Both
re thought to play an important role in cell survival and
raft adhesion.14-17
With this technique, we have already obtained several
atisfactory results in treating myocardial infarction in some
nimal models.14,15 We next hypothesized that this innov-
ive graft could be applicable to the treatment of DCM.
herefore, we designed a preclinical study to test the fea-
ibility and usefulness of using these myoblast sheets as
rafts to treat end-stage DCM in large mammals.
aterials and Methods
apid Pacing–induced Canine Heart Failure Model
welve adult female beagles weighing 8 to 10 kg were used in this
xperiment. All animals received humane care in compliance with
he “Principles of Laboratory Animal Care” formulated by the
ational Society for Medical Research and the “Guide for the Care
nd Use of Laboratory Animals” prepared by the Institute of
aboratory Animal Resource and published by the National Insti-
utes of Health (NIH publication No. 85-23, 1996).
The dogs were anesthetized with intravenous administration of
etamine (6 mg/kg) and sodium pentobarbital (6 mg/kg), intubated
ndotracheally, and given mechanical ventilation. Anesthesia was
aintained with inhaled sevoflurane (1.0%2.0%). Under sterile
onditions, a bipolar pacing lead (Star Medical BT-45P; Star
edical, Tokyo, Japan) was surgically fixed to the right ventric-
Abbreviations and Acronyms
CK  color kinesis
DCM  dilated cardiomyopathy
FS  fractional shortening
LV  left ventricular
LVAWTh  left ventricular anterior wall thickness
LVEF  left ventricular ejection fraction
LVESA  end-systolic LV area
PCNA  proliferating cell nuclear antigen
TUNEL  terminal deoxynucleotidyl transferase-
mediated dUTP nick end labelinglar free wall surface and connected to a pulse generator (Star t
The Journal of Thoracicedical SIP-501; Star Medical) placed in a subcutaneous pocket.
he muscle and skin were closed in layers, and the dogs were then
aken off the anesthetics. Their heartbeats were monitored during
nd after the operation for a few hours to check for arrhythmia.
ne day after the operation, rapid ventricular pacing was started at
rate of 230 beats/min. The pacing was temporarily stopped
uring the assessment of cardiac function and during surgery. The
ate control of the implanted pulse generator was manipulated
eyond the cutis using a magnet with the animal awake.
reparation of Skeletal Myoblast Sheets for Grafting
ith the dog under general anesthesia, skeletal muscle weighing
pproximately 2 g was removed from the pretibial region. After the
ddition of trypsin-EDTA (Gibco, Grand Island, NY), excessive
onnective tissue was carefully removed using 26G needles to
inimize the content of contaminating fibroblasts, and the muscle
issue was minced until the fine pieces formed a homogeneous
ass. The specimens were then incubated at 37° in a shaker bath
ith 0.5% type I collagenase (Gibco) in Dulbecco’s modified
agle’s medium (Gibco). After brief placement, the fluid was col-
ected, and the same volume of culture medium, SkBM (Cambrex,
alkersville, Md) supplemented with fetal bovine serum (Thermo
race, Melbourne, Australia), was added to halt the enzymatic
igestion process. The cells were collected by centrifugation, and
he putative myoblasts were seeded into five 150-cm2 polystyrene
asks after removal of fibroblasts by sedimentation for a few hours
nd cultured in SkBM at 37°. During the culture process, we
aintained cell densities at less than 70% confluence by carrying
ut passaging of cells for 1 time to prevent skeletal myoblasts from
remature differentiation and fusion process resulting in myotubes
ormation. When the cells became approximately 70% confluent
fter 10 to 11 days cultivation (Figure 1, A) the cells wer
issociated from the flasks with trypsin-EDTA and reincubated on
0-mm temperature-responsive culture dishes (Cellseed, Tokyo,
apan) at 37° with the cell numbers adjusted to 1.52.5  106 per
ish. More than 90% of these cells were desmin positive (data not
hown). After 24 hours, the dishes were moved to a refrigerator set
t 20° and left there for 30 minutes. During that time the myoblast
heets detached spontaneously from the surfaces (Figure 1,B).
lmost all of the seeded myoblasts were organized into the graft,
nd there was hardly any loss of cells. Each sheet had a diameter
f 30 to 40 mm and consisted of layers of skeletal myoblasts; the
heets were approximately 90-m thick (Figure 1, C). Approxi-
ately 20 sheets were obtained from the original 2 g of skeletal
uscle.
rafting the Myoblast Sheets
fter 28 days of rapid ventricular pacing, the autologous skeletal
yoblast sheets were grafted onto the left ventricle (Tx group, n
) or a sham operation was performed (C group, n  7). The
urgical approach was through a left-sided thoracotomy under
eneral anesthesia with the pacemaker off. In the Tx group, 18 to
1 sheet grafts were implanted onto the surface of the anterior and
ateral left ventricular (LV) wall so that each dog received 4.0 
07 cells in total. Basically, we tried to implant as many sheets as
ossible onto the visible heart surface from the operative field.
ecause piling up 4 or more sheets caused the central necrosis ofhe myoblasts, presumably as a result of the lack in oxygen supply,
and Cardiovascular Surgery ● Volume 132, Number 4 919
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CSPe decided to pile 3 layers of the myoblast sheet over the broad
urface of the impaired heart. When the grafts were applied, they
ere smoothed out on the LV wall, where surface tension kept
hem stuck tightly to the epicardium in most cases (Figure D).
f necessary, the implanted grafts were fixed at several points with
-0 polypropylene epicardial sutures. In the C group, a left-sided
horacotomy and incisions in the pericardium were performed. The
apid pacing was restarted the day after surgery and was main-
ained at the same rate as before.
easurement of Canine Cardiac Function
t the prepacing state, baseline (just before the graft implantation
r sham operation), and every 2 weeks after the surgical treatment,
ach dog was given general anesthesia and cardiac ultrasonogra-
hy was performed using a SONOS 5500 (Hewlett-Packard, Palo
lto, Calif). The end-systolic and end-diastolic LV areas were
easured at the level of the papillary muscles and mitral valve
LVESApm, LVESAmv, LVEDApm, LVEDAmv). The end-systolic
nd end-diastolic LV dimensions along the long-axis (LVLs,
VLd) were also measured. In addition, we determined the end-
ystolic and end-diastolic LV dimension (LVDs, LVDd), and LV
nterior wall thickness (LVAWTh) in short-axis views in the
-mode. All data are presented as the average of measurements of
selected beats. Simpson’s formula was used to calculate the
nd-systolic and end-diastolic LV volume (LVVs, LVVd). The LV
jection fraction (LVEF) and LV percentage of fractional short-
ning (FS) were calculated as follows, respectively:
(1) LVVs(d)  LVLs(d)/3  {LVES(D)Amv 
[LVES(D)Amv  LVES(D)Apm]/2  LVES(D)Apm/3}
(2) LVEF (%)  [(LVVd  LVVs)/LVVd]  100
(3) LV%FS  [(LVDd  LVDs)/LVDd]  100
chocardiographic Evaluation With Color Kinesis
or the further assessment of LV regional function, we applied
olor kinesis (CK) analysis using the SONOS 5500. Regional wall c
20 The Journal of Thoracic and Cardiovascular Surgery ● Octootion was assessed by computing the pixel counts in each LV
egment; the segment boundaries were automatically determined
y custom-designed software. Regional systolic function was ap-
raised using the regional fractional area changes, which express
he percentage of the end-systolic area of the regional LV wall
otion.18 Regional diastolic function was evaluated using 
K-diastolic index in each region, which was defined as the LV
egmental filling fraction during the first one-third of the diastolic
lling time, and expressed as a percentage.19
istologic Assessment
our weeks after the surgical treatment, the dogs were given an
njection of heparin and then euthanized. The hearts were re-
oved, and at least 4 myocardial samples were excised from
arious regions of the same heart. They were then fixed with 10%
uffered formalin and paraffin-embedded or frozen in liquid nitro-
en. The fixed specimens were sectioned to a 5-m thickness.
ematoxylin-eosin staining and Masson’s trichrome staining were
erformed for the morphometry analysis. To test for the existence
f skeletal muscle cells, sections were incubated with mouse
onoclonal anti-Nebulin (Sigma-Aldrich, St Louis, Mo), which is
pecific for skeletal muscle. To assess the extent of fibrosis, picro-
irius red staining was used, and the proportion of the fibrosis-
ccupying area (percent fibrosis) was calculated. To label vascular
ndothelial cells, immunohistochemical staining for factor VIII-
elated antigen (Dako EPOS Anti-human Von Willebrand Factor/
RP; DakoCytomation, Glostrup, Denmark) was performed. Pe-
iodic acid-Schiff staining was used to label myocytes so their
iameters could be measured. To define proliferative activity, we
sed mouse monoclonal antiproliferating cell nuclear antigen
PCNA) (Sigma-Aldrich). To determine the extent of apoptosis,
ections from frozen tissue samples were subjected to terminal
eoxynucleotidyl transferase-mediated dUTP nick end labeling
TUNEL) with an in situ apoptosis detection kit (Apoptag; Chemi-
Figure 1. Manufacture and grafting of skele-
tal myoblast sheets. A, Primary cultures of
autologous skeletal myoblasts showing a
spindle-shaped appearance. B, Each graft
was soft and limp, with a diameter of 30 to 40
mm. C, Cross-section of a graft, which was
approximately 90-m thick. D, Graft (arrows)
was placed and smoothed out on the LV wall.
Scale bar: 50 m (A, C) and 10 mm (B).on, Temecula, Calif). Computed appraisal of pathology (percent
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Pbrosis, vascular density, myocyte diameter, and percentage of
UNEL-positive nuclei) was performed on 10 randomly chosen
ptical fields (0.56 mm2) for each sample.
tatistical Analysis
ll values are expressed as the means  standard error of mean.
tatistical comparisons of the cardiac function data were per-
ormed using repeated-measures analysis of variance followed by
Bonferroni test for individual significant differences. Histologic
ata were compared using the Student t test.
esults
anine Dilated Cardiomyopathy Model
fter rapid ventricular pacing for 4 weeks, all of the dogs
eveloped marked LV dysfunction with a dilated chamber
Figure 2). Neither critical arrhythmia nor any other c
lication associated with graft implantation was identified in
ny of the dogs after the surgical procedure.
mplantation of Myoblast Grafts Improved Cardiac
unction
he echocardiography showed significant improvement of
VEF and LV percentage of FS in the Tx group between
re-Tx and 4 weeks post-Tx. It also showed significant
mprovement of these systolic functions in the Tx group
ompared with the C group at 2 and 4 weeks after graft
mplantation (Figure 2, A,B). These functional improve
ents were observed as soon as 1 week post-Tx (data not
hown). The Tx group showed a significant increase in
VAWTh and a significant decrease in LVESA compared
ith the C group (Figure 2, C,D). In regard to the LV s
The Journal of Thoracichamber volume, LVVs of the Tx group were significantly
maller than that of the C group (Tx, 426.4  87.1 mL; C,
18.6 82.4 mL; P .05) 4 weeks after graft implantation,
hereas there was no significant difference between the 2
roups at baseline (Tx, 458.1  102.0 mL; C, 441.4  94.4
L). LVVd of the Tx group tended to be smaller than that
f the C group 4 weeks after treatment, although the differ-
nce was not statistically significant (Tx, 584.3  157.7
L; C, 774.6  144.5 mL; P  .10).
In the assessment of regional fractional area changes
n the anterolateral segment, where the myoblast grafts
ere implanted, no significant difference was seen at
aseline between the 2 groups by CK analysis (Tx, 30.4%
5.4%; C, 29.2%  4.2%). Four weeks after the oper-
tion, the regional fractional area changes had increased
ignificantly in the Tx group, whereas it decreased in the
group (Tx, 40.0%  4.0%; C, 25.0%  4.5%; P 
01). In the assessment of regional LV diastolic function,
he CK-diastolic indices in the anterolateral segment
ere significantly different between the 2 groups 4 weeks
fter the operation (Tx, 50.0%  12.0%; C, 34.0% 
.9%; P  .05), although there was no significant differ-
nce between the groups at baseline (Tx, 36.4%  8.0%;
, 35.7%  7.2%). This high value of the CK-diastolic
ndices in the Tx group means that the LV wall could
xpand satisfactorily in the early diastolic phase. These
chocardiographic assessments using CK indicated a
lear improvement of the cardiac performance in the
Figure 2. Echocardiographic findings. LVEF
(A), LV%FS (B), and LVAWTh (C) increased,
whereas LVESA (D) decreased after implan-
tation in the Tx group. Data are expressed
as the means standard error of mean. *P<
.05 versus the C group. #P < .05 versus the
baseline.ystolic and diastolic function in the Tx group.
and Cardiovascular Surgery ● Volume 132, Number 4 921
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CSPraft Survival and Attenuation of Cardiac
emodeling After Graft Implantation
acroscopic examinations confirmed that LV dilatation
as generally inhibited and that the LV wall thickness was
aintained in the Tx group compared with the C group
Figure 3, A,B). In the Tx group, no tumor formation
rafted cells was observed. There was a thin layer of whitish
issue on the surfaces of the anterior and lateral LV walls,
hich coincided with the sites of implantation of the grafts.
icroscopic examination of the whitish tissue revealed
longated skeletal muscle cells in some layers over the
picardium (Figure 3, C,D); these were confirmed to be
keletal origin by staining for skeletal muscle-specific nebu-
in (Figure 3, E). In the same region of the grafted cell l
oderate angiogenesis and infiltration of inflammatory cells
ere also observed.
In the native myocardial tissue, picrosirius red staining
howed an obvious reduction of fibrosis in the Tx group
ompared with the C group (Figure 3, F,G), and fibrosis wa
lso significantly reduced (Tx, 0.3%  0.1%; C, 2.6%  g
22 The Journal of Thoracic and Cardiovascular Surgery ● Octo,
.6%; P  .05). Vascular density in the Tx group was higher
han in the C group, although the difference was not significant
Tx, 15.8%  5.4%; C, 12.9%  3.6%). PCNA-positive cells
ere identified only in the Tx group (23.7  3.8/mm2) (Figure
, H,I), and some of them appeared to be myocardial cells
striated pattern and long thin nuclei; the remainder appeared
o be interstitial cells (Figure 3, J). The percentage of TUNE
ositive myocytes was significantly lower in the Tx group
han in the C group (Tx, 0.16%  0.10%; C, 0.45% 
.16%; P  .05) (Figure 3, K,L). The mean diameter of t
yocytes in the Tx group was smaller than in the C group,
lthough the difference was not significant (Tx, 13.1  1.4
m; C, 16.3  2.9 m). These histologic findings were
niversally identified in the native myocardial tissue with-
ut distinction of distance from the grafted region.
iscussion
n the present preclinical study, we demonstrated that
Figure 3. Postsurgical histologic findings.
Macroscopic findings of cross-sectional spec-
imens of canine heart. Tx group (A) showed an
increased LV wall thickness and decreased
LV thickness, compared with C group (B). Pho-
tomicrograph of a section through the ventric-
ular wall that was stained with hematoxylin-
eosin and contained grafted cells that survived
and formed layers over the epicardium (C).
Higher magnification showing elongated skel-
etal myoblasts (arrows) with infiltrated, round
inflammatory cells (D). Survival of the grafted
myoblasts was confirmed in adjacent sections
by staining with skeletal muscle-specific nebu-
lin (E). Picrosirius red staining showed a sig-
nificant reduction of fibrosis in Tx group (F)
compared with C group (G). PCNA-positive
cells were found in some areas of the myo-
cardium in Tx group (arrows) (H), but none
were identified in the C group (I). Higher
magnification of PCNA-positive cells includ-
ing cardiomyocyte with striated pattern (ar-
rows) and interstitial cells (arrowhead) (J).
The number of TUNEL-positive myocytes (ar-
rows) was significantly lower in Tx group (K)
than in C group (L). Scale bar: 20 mm (A, B);
100m (C, F-I, K, L); 40m (D, E); and 20m (J).rafted autologous skeletal myoblast sheets attenuated car-
ber 2006
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Piac remodeling and improved LV systolic and diastolic
unction in a canine model of DCM. This study differs from
ther reported cardiomyoplasty methods in that the appli-
ation of these grafts allowed us to address diffuse lesions
nd reduce cell loss. To the best of our knowledge, this is
he first report in which grafts of tissue-engineered myoblast
heets were successfully used to improve cardiac perfor-
ance in a large animal model of DCM.
Over the past decade, regenerative therapies based on
ell Tx have been explored as potential novel approaches
or the treatment of end-stage heart failure. Among the
any candidate cells, skeletal myoblasts have been consid-
red to have several advantages, including autologous ori-
in, ease of procurement, high proliferative potential in
itro, and strong resistance to hypoxia followed by isch-
mia.2,4 Thus, they are one of the cell sources that is 
trongly expected to be successful for cell Tx therapy in
linical applications.
Although accumulated experimental and clinical results
ave demonstrated the feasibility and efficacy of transplant-
ng skeletal myoblasts to treat ischemic cardiomyopa-
hy,11,12 limited preclinical data are available on the tr-
ent of DCM.20 In the present study, we used the 
apid-pacing heart failure model, which is known to simu-
ate human DCM, not only in terms of cellular and molec-
lar changes but also in terms of the resulting functional and
tructural characteristics.21,22 In this model, as in hum
diopathic DCM, cell death by apoptosis may play a signif-
cant role in cardiac failure.23-25 The loss of myocytes lea
o interstitial fibrosis and edema, hypertrophy of the surviv-
ng myocytes, and chamber dilation. As a consequence of
his myocardial remodeling, cardiac function both deterio-
ates and decompensates. Thus, it was very important to
nvestigate these pathologic changes in considering the clin-
cal application of our therapy.
We are still uncertain how such thin sheets of myoblasts
nd the relatively small volume of grafted cells that survived
utside the epicardium could inhibit cardiac remodeling
nd induce improvement in cardiac function. The number
f surviving myoblasts may be too small for these cells to
ake such a dramatic contribution by themselves. One of
he most likely mechanisms we have speculated about is a
aracrine effect of growth factors secreted from the skeletal
yoblasts, such as hepatocyte growth factor. Our patho-
ogic findings, including the antifibrotic and antiapoptotic
ffects, angiogenesis, and proliferation of myocytes, were
onsistent with the reported effects of hepatocyte growth
actor and vascular endothelial growth factor.26,27 In fact,
atsumi and colleagues28 reported that hepatocyte growt
actor is present in adult skeletal muscle. Moreover, our
ecent research also revealed that not only hepatocyte
rowth factor but also other growth factors, including stromal-
ell derived factor-1 and vascular endothelial growth factor, M
The Journal of Thoracict
re highly expressed by the skeletal myoblast sheets in vitro
nd in vivo.14 Thus, although we have not assessed 
xpression of these growth factors here, we think there is a
ood possibility that they play an important role in cardio-
yoplasty. Several PCNA-positive cells with striated pat-
ern were identified in the implantation group, but none
ere observed in the control group. This may suggest an-
ther possible mechanism that the immigrated and prolifer-
ting cells in the myocardium have active and passive
ffects that may increase ventricular contractility and de-
rease LV wall stress.12,13 If these speculative mechanism
re operative in vivo, it may not be necessary for the grafted
ells to infiltrate into the native myocardium to exert their
ffects.
Beneficial for cell Tx therapy, the myoblast sheets had a
reserved extracellular matrix and intracellular junctions,
hich may be essential to the primary attachment and
urvival of the grafted cells.14-17
Several important aspects of this method remain to be
esearched. The first is that a longer-term assessment of the
utcome is needed. Second, the optimum number of myo-
lasts and/or layers of sheets needs to be determined. Al-
hough we obtained favorable results by applying 3 layers of
rafts in the present study, it is unclear whether still greater
mprovement would be achieved by increasing the number
f graft layers or fewer graft numbers could affect the same
mount of improvement. Third, the optimal timing for the
mplantation of myoblast grafts with respect to the stage of
he disease also needs to be investigated. In the canine heart
ailure model used here, heart function recovers quickly
fter the cessation of rapid ventricular pacing.22 Therefore,
t remains uncertain when a decompensated and irreversible
tate of heart failure has been attained and whether such
omplete failure can be reversed by this therapy. Additional
tudies are required to determine the optimum timing of this
reatment for clinical trials.
onclusions
e found that the present novel cell delivery system using
heets of autologous skeletal myoblasts as grafts was satis-
actorily feasible and effective for treating global heart
ailure. Because pathologic similarities exist between this
anine experimental model and human DCM, the present
ethod is a promising regeneration therapy that may pro-
ide great benefit to patients with chronic heart failure
aused by DCM.
We thank Dr Satoru Kitagawa-Sakakida for critical review of
he article, Mrs Masako Yokoyama for expert assistance with
everse transcriptase-polymerase chain reaction, and Mr Shigeruatsumi for excellent technical support.
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